Analyst firms · Leerink Partners · NPCE
Leerink Partners NPCE price target and rating history
Neuropace Inc. (NPCE) · Health Care
Leerink Partners rates Neuropace Inc. (NPCE) Market Perform with a $7 price target, as of its latest action on Nov 13, 2026. It has published 3 rating actions on NPCE since March 2022, including 0 upgrades and 1 downgrade. Across 4 firms with a NPCE price target in the last 12 months, the median target is $13.50. Leerink Partners's $7 is 48% below that.
- Current rating
- Market Perform
- Price target
- $7
- Median target, all firms
- $13.50
- Actions on NPCE
- 3
Leerink Partners price target on NPCE
Every Leerink Partners rating on NPCE
- Nov 13, 2026
- Jan 30, 2024
- Mar 11, 2022
How other firms rate NPCE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wells Fargo | Equal Weight | $9 | Nov 13, 2026 |
| Leerink Partners | Market Perform | $7 | Nov 13, 2026 |
| KeyBanc Capital Markets | Overweight | $18 | Sep 18, 2026 |
| Mizuho | Outperform | $22 | Jul 23, 2026 |
Questions about Leerink Partners and NPCE
- What is Leerink Partners's price target for NPCE?
- Leerink Partners's latest stated price target for Neuropace Inc. (NPCE) is $7, from its action on Nov 13, 2026.
- What is Leerink Partners's rating on NPCE?
- Leerink Partners rates NPCE Market Perform, a neutral rating, as of Nov 13, 2026.
- When did Leerink Partners last change its view on NPCE?
- On Nov 13, 2026, Leerink Partners downgrades to Market Perform from Outperform, price target $7.
- How does Leerink Partners's NPCE target compare with other analysts?
- Across 4 firms with a NPCE price target in the last 12 months, the median target is $13.50. Leerink Partners's $7 is 48% below that.
More NPCE rating histories
All Leerink Partners ratingsNPCE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.